<sup>192</sup>Ir近距离治疗在局部复发非小细胞肺癌中的应用

doi:10.3760/cma.j.cn113030-20200817-00419

摘要
图/表
参考文献
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的探讨局部复发非小细胞肺癌采用¹⁹²Ir近距离治疗的疗效和安全性。方法收集河北省沧州中西医结合医院自2013—2018年间调强放疗后局部复发的非小细胞肺癌22例。采用¹⁹²Ir高剂量率近距离治疗复发病灶,处方剂量30Gy1次,治疗后前3个月每1个月复查CT,3个月后每3个月复查CT,评价局控率、不良反应,复发治疗后1、2年总生存率。结果 22例患者均顺利完成治疗,1、3、6个月病灶完全缓解率分别为9%、14%、14%,部分缓解率分别为82%、82%、82%,疾病稳定率分别为5%、0%、0%,疾病进展率分别为5%、5%、5%;有效率分别为91%、96%、96%。复发治疗后1、2年总生存率分别为59%、27%。急性放射性肺炎5例占23%(1级3例、2级2例),骨髓抑制4例占18%(白细胞减少1级3例、血小板减少1级1例),术后气胸1例,给予对症治疗后均好转。结论 ¹⁹²Ir近距离治疗局部复发非小细胞肺癌安全有效、不良反应可耐受。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：局部复发, 肺肿瘤/近距离疗法, 治疗结果, 不良反应

Abstract：Objective To evaluate the clinical efficacy and adverse events of ¹⁹²Ir high-dose rate brachytherapy (HDR-BT) in the treatment of locally recurrent non-small cell lung cancer (NSCLC). Methods Clinical data of 22 cases of recurrent NSCLC after radiotherapy admitted to our hospital from September 2013 to March 2018 were retrospectively analyzed. ¹⁹²Ir HDR-BT was adopted for reradiotherapy. The prescription dose was 30Gy for 1 fraction. CT scan was reviewed every 1 month in the first 3 months after treatment and every 3 months after 3 months. Local control rate and adverse events were evaluated. The 1-and 2-year overall survival (OS) rates of re-treatment after relapse were calculated. Results All the 22 patients completed the treatment successfully. The 1-, 3-and 6-month complete response (CR) rates were 9%, 14% and 14%, 82%, 82% and 82% for the partial response (PR) rates, 5%, 0% and 0% for the stable disease (SD) rates, 5%, 5% and 5% for the progressive disease (PD) rates, 91%, 96% and 96% for the Objective response rates (ORR), respectively. The 1-and 2-year OS rates of re-treatment after relapse were 59% and 27%. Five patients (23%) experienced acute radiation-induced pneumonitis (3 cases of grade 1 and 2 cases of grade Ⅱ), 4 cases (18%) of radiation-induced bone marrow suppression (3 cases of grade I leukopenia and 1 case of grade I thrombocytopenia) and 1 case of postoperative pneumothorax. All these adverse events were mitigated after symptomatic treatment.Conclusion ¹⁹²Ir HDR-BT is an efficacious and safe treatment of locally recurrent NSCLC.

Key words： Locally recurrent,lung neoplasm/brachytherapy Treatment outcome Adverse event

收稿日期: 2020-08-17

通讯作者: 孙云川,Email:13932719095@163.com

引用本文:

. ¹⁹²Ir近距离治疗在局部复发非小细胞肺癌中的应用[J]. 中华放射肿瘤学杂志, 2021, 30(8): 775-779.

. Application of ¹⁹²Ir brachytherapy in locally recurrent non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2021, 30(8): 775-779.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20200817-00419 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2021/V30/I8/775

[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI:10.3322/caac.21338.
[2] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108. DOI:10.3322/caac.21262.
[3] 吴敬波,张建文,向莉,等. CT引导下周围型肺癌插植三维后装放疗初探[C]//中华医学会第九次全国放射肿瘤治疗学学术会议论文集. 北京:中华医学会放射肿瘤治疗学分会,2012:399-400.
Wu JB, Zhang JW, Xiang L, et al. Preliminary study on CT guided three-dimensional brachytherapy for peripheral lung cancer[C]. Proceedings of the 9^th national conference on radiation oncology of Chinese Medical Association,Beijing:Radioactive Oncology Therapy Branch of the Chinese Medical Association, 2012:399-400.
[4] 尹晓明,孙云川,胡婷婷,等.¹⁹²Ir高剂量率近距离治疗在结直肠癌术后复发肺内寡转移治疗的初步应用[J]. 中华放射医学与防护杂志,2019, 39(11):833-836. DOI:10.3760/cma.j.issn.0254-5098.2019.11.006.
Yin XM, sun YC, Hu TT, et al. Preliminary application of ¹⁹²Ir high dose rate brachytherapy in the treatment of postoperative recurrent pulmonary oligo metastasis of colorectal cancer[J]. Chin J Radiol Med Prot, 2019, 39(11):833-836. DOI:10.3760/cma.j.issn.0254-5098.2019.11.006.
[5] Ohguri T, Imada H, Yahara K, et al. Re-irradiation plus regional hyperthermia for recurrent non-small cell lung cancer:a potential modality for inducing long-term survival in selected patients[J]. Lung Cancer, 2012, 77(1):140-145. DOI:10.1016/j.lungcan.2012.02.018.
[6] Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(13):2181-2190. DOI:10.1200/JCO.2009.26.2543.
[7] Trovo M, Minatel E, Durofil E, et al. Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2014, 88(5):1114-1119. DOI:10.1016/j.ijrobp.2014.01.012.
[8] 徐秀理,胡宗涛,芦东徽,等. 局部复发非小细胞肺癌SRT再程放疗近期疗效及不良反应观察[J]. 中华放射肿瘤学杂志,2019, 28(7):495-498. DOI:10.3760/cma.j.issn.1004-4221.2019.07.004.
Xu XL, Hu ZT, Lu DH, et al. Observation of short-term clinical efficacy and adverse reactions with stereotactic radiotherapy in locally recurrent non-small cell lung cancer[J]. Chin J Radiat Oncol, 2019, 28(7):495-498. DOI:10.3760/cma.j.issn.1004-4221.2019.07.004.
[9] Xiang L, Zhang JW, Lin S, et al. Computed Tomography-guided interstitial high-dose-rate brachytherapy in combination with regional positive lymph node intensity-modulated radiation therapy in locally advanced peripheral non-small cell lung cancer:a phase 1 clinical trial[J]. Int J Radiat Oncol Biol Phys,2015, 92(5):1027-1034. DOI:10.1016/j.ijrobp.2015.04.019.
[10] Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage Ⅰ nonsmall cell lung carcinoma:clinical outcomes in 245 subjects in a Japanese multⅡnstitutional study[J]. Cancer, 2004, 101(7):1623-1631. DOI:10.1002/cncr.20539.
[11] Kim MS, Kim W, Park IH, et al. Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery[J]. Radiat Oncol J, 2015, 33(4):265-275. DOI:10.3857/roj.2015.33.4.265.
[12] Manning MA, Zwicker RD, Arthur DW, et al. Biologic treatment planning for high-dose-rate brachytherapy[J]. Int J Radiat Oncol Biol Phys, 2001, 49(3):839-845. DOI:10.1016/s0360-3016(00)01453-x.
[13] Roses RE, Datta J, Czerniecki BJ. Radiation as immunomodulator:implications for dendritic cell-based immunotherapy[J]. Radiat Res, 2014, 182(2):211-218. DOI:10.1667/RR13495.1.
[14] Wattenberg MM, Fahim A, Ahmed MM, et al. Unlocking the combination:potentiation of radiation-induced antitumor responses with immunotherapy[J]. Radiat Res, 2014, 182(2):126-138. DOI:10.1667/RR13374.1.
[15] Okamoto Y, Murakami M, Yoden E, et al. Reirradiation for locally recurrent lung cancer previously treated with radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2002, 52(2):390-396. DOI:10.1016/s0360-3016(01)02644-x.
[16] 杨肖华,黄新宇,汪国祥等. CT引导下经皮肺穿刺活检术并发症的影响因素分析[J]. 介入放射学杂志,2013, 22(8):658-662. DOI:10.3969/j.issn.1008-794X.2013.08.011.
Yang XH, Huang XY, Wang GX, et al. Complications of CT-guided percutaneous lung puncture biopsy:an analysis of influencing factors[J]. J Int Radiol, 2013,22(8):658-662. DOI:10.3969/j.issn.1008-794x.2013.08.011.
[17] 杨波,孙小杨,庞皓文,等. 肺癌插植放疗中插植针排列规则对肺受量影响研究[J]. 中华放射肿瘤学杂志, 2017, 26(12):1417-1420. DOI:10.3760/cma.j.issn.1004-4221.2017.12.013.
Yang B, Sun XY, Pang HW, et al. Effect of needle arrangement on the lung dose in interstitial brachytherapy for lung cancer[J]. Chin J Radiat Oncol, 2017, 26(12):1417-1420. DOI:10.3760/cma.j.issn.1004-4221.2017.12.013.